Latest Data


« Your Comments? Our Youth Still Exposed To Smokeless Tobacco Ads Despite Settlement | Main | Topic Misdiagnosis Of Pancreatic Cancer Can Be Caused By A Tumor Marker Ca 19-9 In Diabetics »

Join The Fight Against Cancer Merck Serono: Stimuvax® Therapeutic Cancer Vaccine - Phase Ii Data Highlight Three-year Survival Results For Lung Cancer Patients

By admin2 | October 29, 2007

MedicalMerck Serono announced three year survival results from a randomized Phase II trial for the Stimuvax MUC-1 vaccine in non-small cell lung cancer (NSCLC) at the International Association for the Study of Lung Cancer (IASLC) Congress in Seoul, South Korea. [click link for full article]
(Link)

This entry was important to me: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • StumbleUpon
  • Digg
  • del.icio.us
  • Reddit
  • Furl
  • Junipo

Topics: Cancer |

Comments